Literature DB >> 20036904

Emax model and interaction index for assessing drug interaction in combination studies.

J Jack Lee1, Heather Y Lin, Diane D Liu, Maiying Kong.   

Abstract

Applying the Emax model in a Lowe additivity model context, we analyze data from a combination study of trimetrexate (TMQ) and AG2034 (AG) in media of low and high concentrations of folic acid (FA). The Emax model provides a sufficient fit to the data. TMQ is more potent than AG in both low and high FA media. At low TMQ:AG ratios, when a smaller amount of the more potent drug (TMQ) is added to a larger amount of the less potent drug (AG), synergy results. When the TMQ:AG ratio reaches 0.4 or larger in low FA medium, or when the TMQ:AG ratio reaches 1 or larger in high FA medium, synergy is weakened and drug interaction becomes additive. In general, synergistic effect in a dilution series is stronger at higher doses that produce stronger effects (closer to 1-Emax) than at lower dose levels that produce weaker effects (closer to 1). The two drugs are more potent in the low compared to the high FA medium. Drug synergy, however, is stronger in the high FA medium.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20036904      PMCID: PMC2974574          DOI: 10.2741/e116

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  21 in total

1.  On testing for drug/chemical interactions: definitions and inference.

Authors:  C Gennings
Journal:  J Biopharm Stat       Date:  2000-11       Impact factor: 1.051

2.  Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.

Authors:  M M Nyunt; C V Plowe
Journal:  Clin Pharmacol Ther       Date:  2007-09-26       Impact factor: 6.875

3.  Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction.

Authors:  J Jack Lee; Maiying Kong
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

Review 4.  What is synergy?

Authors:  M C Berenbaum
Journal:  Pharmacol Rev       Date:  1989-06       Impact factor: 25.468

5.  Asymptotic confidence bands for generalized nonlinear regression models.

Authors:  C Cox; G Ma
Journal:  Biometrics       Date:  1995-03       Impact factor: 2.571

6.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

Review 7.  Advances in chemotherapy of non-small cell lung cancer.

Authors:  Julian R Molina; Alex A Adjei; James R Jett
Journal:  Chest       Date:  2006-10       Impact factor: 9.410

Review 8.  Future options for imatinib mesilate-resistant tumors.

Authors:  Kamalesh K Sankhala; Kyriakos P Papadopoulos
Journal:  Expert Opin Investig Drugs       Date:  2007-10       Impact factor: 6.206

Review 9.  Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.

Authors:  Roberto Bianco; Vincenzo Damiano; Teresa Gelardi; Gennaro Daniele; Fortunato Ciardiello; Giampaolo Tortora
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

Review 10.  Molecularly targeted therapy for malignant glioma.

Authors:  Sith Sathornsumetee; David A Reardon; Annick Desjardins; Jennifer A Quinn; James J Vredenburgh; Jeremy N Rich
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

View more
  3 in total

1.  Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction.

Authors:  J Jack Lee; Maiying Kong
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

2.  Robust and Efficient Assessment of Potency (REAP) as a quantitative tool for dose-response curve estimation.

Authors:  Shouhao Zhou; Xinyi Liu; Xinying Fang; Vernon M Chinchilli; Michael Wang; Hong-Gang Wang; Nikolay V Dokholyan; Chan Shen; J Jack Lee
Journal:  Elife       Date:  2022-08-03       Impact factor: 8.713

3.  Applying Emax model and bivariate thin plate splines to assess drug interactions.

Authors:  Maiying Kong; J Jack Lee
Journal:  Front Biosci (Elite Ed)       Date:  2010-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.